Loading...
XNAS
ACHV
Market cap131mUSD
Jul 22, Last price  
2.65USD
1D
-0.38%
1Q
9.05%
Jan 2017
-95.18%
Name

Achieve Life Sciences Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
138.88%
Rev. gr., 5y
%
Revenues
0k
8,254,48322,391,85820,130,66320,131,00025,539,00013,616,0005,496,00020,095,00029,882,00027,116,00018,160,0005,062,00000000000
Net income
-40m
L+33.58%
-21,097,017-23,551,296-13,063,168-4,204,0005,476,000-12,584,000-14,673,000-21,098,000-31,849,000-26,240,000-16,801,000-20,129,000-10,583,000-12,687,000-16,141,000-14,661,000-32,902,000-41,875,000-29,815,000-39,827,000
CFO
-30m
L+21.61%
-8,359,213-19,680,553-23,335,332-12,307,00034,878,000-26,840,000-20,263,000-43,493,000-35,927,000-17,308,000-9,101,000-29,683,000-9,107,000-10,623,000-15,216,000-13,474,000-29,440,000-37,549,000-24,479,000-29,770,000
Earnings
Aug 11, 2025

Profile

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
URL
http://achievelifesciences.com/
IPO date
Oct 12, 1995
Employees
20
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
39,069
27,478
41,036
Unusual Expense (Income)
NOPBT
(39,069)
(27,478)
(41,036)
NOPBT Margin
Operating Taxes
(39,827)
(475)
Tax Rate
NOPAT
758
(27,478)
(40,561)
Net income
(39,827)
33.58%
(29,815)
-28.80%
(41,875)
27.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
56,076
15,271
19,212
BB yield
-49.67%
-18.69%
-74.03%
Debt
Debt current
55
16,725
58
Long-term debt
9,969
75
16,267
Deferred revenue
Other long-term liabilities
1,149
Net debt
(24,336)
1,204
(8,496)
Cash flow
Cash from operating activities
(29,770)
(24,479)
(37,549)
CAPEX
(21)
Cash from investing activities
(21,580)
(21)
Cash from financing activities
48,527
15,278
19,295
FCF
718
(27,434)
(40,605)
Balance
Cash
34,360
15,546
24,771
Long term investments
50
50
Excess cash
34,360
15,596
24,821
Stockholders' equity
(205,444)
(165,657)
(135,845)
Invested Capital
237,450
180,940
160,346
ROIC
0.36%
ROCE
EV
Common stock shares outstanding
32,071
19,827
10,593
Price
3.52
-14.56%
4.12
68.16%
2.45
-68.51%
Market cap
112,890
38.20%
81,689
214.76%
25,953
-58.92%
EV
88,554
82,893
17,457
EBITDA
(38,840)
(27,250)
(40,800)
EV/EBITDA
Interest
2,180
2,853
1,789
Interest/NOPBT